---
title: "RBC Capital Keeps Their Hold Rating on Elevance Health (ELV)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301342699.md"
description: "In a report released on October 7, Ben Hendrix from RBC Capital maintained a Hold rating on Elevance Health, with a price target of $424.00. The company’s shares closed yesterday at $404.31. According to TipRanks, Hendrix is a 4-star analyst with an average return of 6.2% and a 51.71% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Cigna, and Universal Health. Elevance Health has an analyst consensus of Moderate Buy, with a price target consensus of $446.40."
datetime: "2026-10-09T01:47:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301342699.md)
  - [en](https://longbridge.com/en/news/301342699.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301342699.md)
generator: "portal-rs"
---

# RBC Capital Keeps Their Hold Rating on Elevance Health (ELV)

In a report released on October 7, Ben Hendrix from RBC Capital maintained a Hold rating on Elevance Health, with a price target of $424.00. The company’s shares closed yesterday at $404.31.

According to TipRanks, Hendrix is a 4-star analyst with an average return of 6.2% and a 51.71% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Cigna, and Universal Health.

Elevance Health has an analyst consensus of Moderate Buy, with a price target consensus of $446.40.

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)
- [CI.US](https://longbridge.com/en/quote/CI.US.md)
- [HCA.US](https://longbridge.com/en/quote/HCA.US.md)
- [UHS.US](https://longbridge.com/en/quote/UHS.US.md)

## Related News & Research

- [Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302684364.md)
- [Elevance Health, Inc. $ELV Stock Position Cut by Vontobel Holding Ltd.](https://longbridge.com/en/news/302257360.md)
- [ELV: Q3 outperformance lifts 2026 guidance; long-term adjusted EPS growth target remains 12%](https://longbridge.com/en/news/302542475.md)
- [Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance | ELV Stock News](https://longbridge.com/en/news/302545860.md)
- [Elevance Health Q3 2026 net income rises 13% year over year to $1.34 billion](https://longbridge.com/en/news/302542349.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**